Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 12, Issue 3, Pages 473-488Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2011.552429
Keywords
aripiprazole; bipolar depression; bipolar disorder; mania
Categories
Funding
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Lundbeck
- Eli Lilly
- Jannssen
- Novartis
- Pfizer
- Sigma Tau
- Takeda
- Servier
Ask authors/readers for more resources
Areas covered: This paper comprises a review and commentary regarding the use of oral and intramuscular aripiprazole in the acute and maintenance phases of bipolar disorder. Basic principles in dosing, switching, management of side effects and co-administration of aripiprazole with other medications are provided. This paper presents practical strategies to translate the data from clinical research into clinical practice. Expert opinion: Aripiprazole has proven to be an effective medication for the acute treatment of manic and mixed episodes, as well as for the prophylactic--maintenance phase of bipolar disorder in patients recovering from a manic/mixed episode. Choosing the appropriate dosing and tapering strategy, addressing the side effects, controlling withdrawal symptoms from previous medications and using adjunctive medications when necessary are key to successful treatment with aripiprazole.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available